secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2023-09-19T23:59:59+00:00
Accession:  0001104659-23-101773
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune names Emily Hill as CFO; previously CFO of PTC Therapeutics
---------------------------------------------------------------------

- Appointed Emily Hill as CFO effective Sept 18, 2023; she was previously CFO of PTC Therapeutics.
- Base salary $495,000, target bonus 40%, plus 125,000 stock options at $18.00 and 83,330 RSUs, vesting over 4 years.
- Termination benefits: 12 months salary plus COBRA; enhanced upon change of control.
- Ms. Hill brings 15+ years biotech experience, including roles at PTC, Warner Chilcott, and Genzyme.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465923101773/0001104659-23-101773-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465923101773/tm2326363d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-101773

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer